Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults.
Introduction
Glioblastoma multiforme (GBM) is a metabolically active, primary adult brain tumor that evades multimodal therapy leading to short survival times. GBM patients have poor prognosis despite surgery and adjuvant chemoradiation with the majority dying within two years. This is commonly attributed to the diverse and heterogeneous signaling mechanisms present in GBM that overcome pharmacotherapy. On the contrary, pervasive metabolic signatures have been identified, particularly the dependence upon glycolysis rather than oxidative phosphorylation (OXPHOS) with elevated lactate production regardless of oxygen availability. This bioenergetic state, when associated with increased glucose metabolism, results in tumorigenesis and tumor progression and a phenomenon termed the Warburg effect (1) (2) (3) (4) (5) (6) . The end result is such that despite functionally complex pathways, convergence occurs to some degree at the mitochondrial level. These metabolically active pathways in tumor cells are regulated by an upstream cascade of signaling mechanisms involving known growth factor receptor tyrosine kinases (RTK) implicated in tumorigenesis and in regulating glucose homeostasis (7, 8) . Aberrant receptor kinase signaling is the primary mode contributing to malignant phenotypes with defined oncogenic signatures in human cancers, including GBM. We propose that the ubiquitous EGFR activation observed in GBM is associated with dysregulated metabolic responses and cell proliferation, making it an ideal target for therapy. However, clinical trials targeting EGFR alone using RTK inhibitors have been met with failure, emphasizing the fact that downstream pathways may serve as the primary modulator of tumor behavior.
Biosciences (San Diego, CA). Trans-AM HIF-1 kit (47596) was purchased from Active Motif (Carlsbad, CA). Isolation of intact mitochondria from cultured GBM cells and surgical biopsies was performed using Mitochondria Isolation Kit (Pierce Biotechnology, Rockford, IL).
Cell Culture
U251 cells were obtained from the American Type Culture Collection (ATCC, Mansas, VA) and were grown in DMEM supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). U251 cell lines were tested and authenticated according to the providers instructions. Xenograft cell line 5310 (a kind gift from Dr. David James at the University of California, San Francisco), authenticated as described previously (15) was grown in RPMI-1640 medium supplemented with 10% FBS and 1%
penicillin-streptomycin at 37°C.
Preparation and culture of human umbilical cord blood stem cells (hUCBSC)
Human umbilical cord blood samples were collected from the umbilical vein of newborns with informed maternal consent according to the protocol approved by the Institutional Review Board at the University of Illinois College of Medicine at Peoria. hUCBSC harvests were processed within 24 h of collection, with viability of more than 90%. Isolation, culture and expansion of hUCBSC were performed as described previously (14) .
Quantitative real-time PCR (qRT-PCR)
The mRNA expression levels of EGFR and PDK1 were detected by qRT-PCR using the iCycler iQ (Bio-Rad; Hercules, CA) in the cDNA isolated from the hGBM biopsies using the primer sequences listed in Supplementary Table 1 
Western blot analysis, immunoprecipitation and immunofluorescence labeling:
Proteins extracted from cultured cells and tissue lysates was followed by immunoprecipitation and immunoblotting with corresponding antibodies, as described previously (14) . Densitometry quantitation was determined using the Image J software (NIH). Equal loading was confirmed by stripping and reprobing the membranes with GAPDH/COX2 antibodies. For immunofluorescence analysis, cells were fixed and incubated with primary antibodies, Alexa
Fluor dye-conjugated secondary antibodies and DAPI according to standard protocols (14) . Cells were examined using Olympus BX61 confocal microscope with a 60-Å oil immersion objective.
SPOT basic and SPOT advanced software was used to deconvolute Olympus BX61 images.
(Diagnostic Instruments; MI).
Immunohistochemistry of hGBM specimens and in vivo tissue sections
hGBM surgical biopsy specimens were obtained from Saint Francis Medical Center, Peoria, IL and processed in accordance with the UICOMP Institutional Review Board-approved protocols.
Serial sections of six human specimens (normal human brain, hGBM-1, hGBM-2, hGBM-3, hGBM-4 and hGBM-5) and mouse xenograft tissue sections were stained with the EGFR, PDK1, HIF-1Į and COX2 antibodies as described previously (14) . Images were acquired by using an Olympus BX61 fluorescence microscope and processed using SPOT advance software.
Transfections and generation of stable cell lines:
Cells were plated at a density of 4X10 5 /60-mm dish 18 h prior to transfection. 
L-Lactate assay from cell culture media and tissue extracts
To measure lactate contents, cells and tissues were extracted with cold 80% ethanol (tissue/solvent ratio 1:8) and centrifuged at 10,000 X g at 4 °C for 30 min. The supernatants were collected and diluted with water at different dilutions. The lactate contents were then assayed using the lactate assay kit (Eton Bioscience; San Diego, CA).
HIF-1Į transcription activity assay
HIF-1Į transcriptional activity was analyzed by using TransAM HIF-1 transcription factor assay kit (Active Motif, Carlsbad, CA) following manufacturer's instructions. Briefly, nuclear extracts were added onto a 96-well micro-plate coated with oligonucleotides containing hypoxia response element (HRE) (59-TACGTGCT-39) from the erythropoietin (EPO) gene. HIF dimers present in nuclear extracts bind with high specificity to this response element and are subsequently detected with an antibody directed against HIF-1Į. Addition of a secondary antibody conjugated to horseradish peroxidase (HRP) provided a sensitive colorimetric readout and was quantified by spectrophotometry. Values are expressed as optical density (OD) at 450 nm with a reference wavelength of 655 nm.
Mitochondria isolation and sub-cellular fractionation
Mitochondrial extracts were prepared using a kit (Pierce; Cat# 89801). Tissues, around 50-200 mg, subjected to fractionation were washed with 2-4mL of PBS and were then cut into small pieces for trypsin treatment, followed by a series of centrifugations to obtain cytosolic and mitochondrial fractions. Mitochondrial proteins (60 μg) and cytosolic proteins (30 μg) were
Research. analyzed by immunoblotting analyses. COX2 (Cytochrome c oxidase subunit II) and GAPDH were used as respective loading controls.
Hypoxia and other treatments
U251 and 5310 cells were exposed to 1-3 cycles of hypoxia and normoxia. Each hypoxic cycle consisted of a period of 24 h in 1% oxygen followed by 24 h recovery under normoxic conditions. During this re-oxygenation period, cells were provided with fresh medium. In another experiment, hypoxic conditions were obtained by incubating cells in 150 ȝmol/L CoCl 2 at different time points as described previously (16) . In another experiment, U251 and 5310 cells were treated with either 5 ȝM Erlotinib or Gefitinib hydrochloride for 9 h; 1 mM DCA for 1 h.
MTT and TUNEL assay:
Cell growth from exponentially growing U251 and 5310 cells; and their respective treatments including si-PDK1, sh-EGFR, DCA (1 mM), Fl-EGFR (Full length EGFR), Fl-EGFR+DCA, FlEGFR+siPDK1 was measured using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazoliumbromide (MTT) assay according to the manufacturer's instructions (Invitrogen; Carlsbad, CA).
To evaluate cell death, TUNEL assay was performed in both U251 and 5310 cells treated with si-PDK1 following manufactures instructions (Roche; Indiana polis, IN).
EGFR phosphorylation antibody array
Around 500 μg of total cell lysates from the 5310-control and treated cells, were subjected to 
Intracranial injections
Fl-EGFR-5310 cells (5X10 5 ) were injected intracranially into four mice per group on the right side of 4-week-old female athymic nude mice under isofluorane anesthesia with the aid of a stereotactic frame. The calvarium of each anesthetized mouse was exposed through a midline incision, and a burr hole was drilled 1 mm lateral (right) and 2 mm anterior to the bregma. Two weeks after tumor implantation, the mice were intravenously injected with 100 mg/kg body weight of DCA. Following tumor cell injection and treatments, mice were observed daily until they reached a moribund state, at which time they were euthanized and their brains removed and processed for histopathologic analysis. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Illinois College of Medicine at Peoria.
Statistical analysis
Statistical analysis and graphical presentation was done using quantitative data from Western blot analysis and other assays were evaluated for statistical significance using GraphPad Prism CAN-13-1868 are the representative images of three independent experiments (n=3) and results are expressed as mean ± SE ( *p<0.05; **p<0.01; ***p<0.001).
Results

EGFR and PDK1 co-express in surgical biopsies of GBM patients.
Activation of EGFR in GBM earlier has shown to increase glucose uptake and lactate production through NF-kB-dependent signaling cascade, promoting tumor development (17) . Studies conducted on aberrant FGFR1 revealed its common existence in tumors regulating the Warburg effect (18) . Recent studies revealed that targeting PDK by DCA shifts cancer cell metabolism from glycolysis to OXPHOS by de-phosphorylating mitochondrial pyruvate dehydrogenase (PDH) (13) . Further, to better understand how tyrosine kinase signaling in conjunction with minimal expression in both experimental conditions ( Figure 1D ). These observations show a novel link between EGFR and PDK1 signaling and suggest that this association might play a critical role in regulating glioma cell metabolism.
DCA treatment and silencing of PDK1 suppresses EGFR expression in GBM.
Previously, we demonstrated the effectiveness of anti-EGFR-targeted therapy using EGFR inhibitors such as erlotinib, gefitinib and AG1478 (14) . Therefore, we sought to investigate the efficacy of these drugs against the gatekeeper of glycolysis, PDK1. Both gefitinib and erlotinib were able to effectively suppress PDK1 and EGFR. However, erlotinib treatment was observed to suppress them more effectively. ( 
Hypoxia mediates EGFR and PDK1 interaction in mitochondria.
It was earlier identified that the gene encoding PDK1 is induced by hypoxia and is a direct target of HIF-1 (19) . Further, Franovic et al. reported a clinical correlation between tumor hypoxia and EGFR expression resulting in tumor progression and poor clinical outcome (20) . In the present study, we exposed U251 and 5310 cells to hypoxia (1% oxygen) or normoxia for 24, 48 and 72 h. In another experiment, we exposed U251 and 5310 to the hypoxia mimicking compound, HIF-1Į expression plausibly controls the receptor tyrosine kinase-(RTK) coupled glioma metabolic pathway. Further, PDK1 is listed as one of the HIF-regulated mitochondrial target genes that mediate functional changes observed in hypoxia (23) . In addition, we conducted immunoblot analysis on the mitochondrial isolates and observed reduced mitochondrial levels of PDK1 and pEGFR in si-PDK1, sh-EGFR treated U251 and 5310 cells, while increased levels were observed in Fl-EGFR treated cells compared to their respective controls. To further confirm PDK1 association with EGFR in the mitochondria, we conducted immunoprecipitation analysis on the mitochondrial lysates obtained from the aforementioned treatments using pEGFR antibody. We observed increased pEGFR-PDK1 interaction in Fl-EGFR treatments, while si-PDK1 and sh-EGFR treatments showed a suppressed interaction ( Figure 3E ). To verify the existence of pEGFR-PDK1 interaction in the mitochondria in hGBM specimens, we performed immuno-co-localization studies with PDK1, pEGFR and COX2 antibodies. We recorded a significant pEGFR(Green)-PDK1(Red)-COX2(Blue) interaction in five hGBM specimens as indicated in white, when compared to the normal counterpart ( Figure 3F ), highlighting the fact that targeting this interaction occurring at the mitochondria might be effective in modulating cell metabolism. Finally, we examined the role of hypoxia in EGFR and PDK1 mitochondrial interaction by immunofluorescence analysis on 48h-induced hypoxic samples. Increased pEGFR and PDK1 mitochondrial localization was observed in both U251 and 5310 hypoxic cells, when compared to their respective normoxic controls ( Figure 3G ). In both the experiments (Figure 3F and 3G; Supplementary Figures 2A and 2B) , we used COX2 to identify mitochondria. These data provide evidence that EGFR-PDK1 interaction at the mitochondria is up-regulated under hypoxia, uncovering a previously uncharacterized mechanism of HIF1-EGFR-PDK1 activation in both GBM cell lines and patient specimens. 
Stem cell treatment inhibits EGFR-PDK1 interaction in vivo
Previously, we showed that human umbilical cord blood stem cells (hUCBSC) reduced EGFR translocation to the mitochondria in GBM cells, highlighting the existence of hUCBSCmediated antagonism of EGFR in mitochondria (24) . In light of our findings that EGFR colocalizes with mitochondrial PDK1 (Figures 3F & 3G 
si-PDK1 induces apoptosis, decreases cell proliferation and lactate release in GBM.
Several papers suggested that targeting metabolically important key enzymes such as pyruvate dehydrogenase kinase (9) , lactate dehydrogenase (9, 25) Figure 5C ). We further examined potential metabolic changes initiated by si-PDK1 treatments in U251 and 5310 cells. Both the control GBM cells showed increased aerobic glycolysis as indicated by increased lactate production; however, si-PDK1, sh-EGFR and DCA treatments maximally reduced the production of lactate. Conversely, Fl-EGFR treatment increased the lactate production, indicating that EGFR overexpression facilitated the induction of aerobic glycolysis. Reduced lactate release in the Fl-EGFR cells exposed to DCA underscores that silencing PDK1-targeting EGFR might effectively reduce lactate production, mitigating cells towards oxidative phosphorylation ( Figure 5D ). Similarly, hUCBSC treatment reduced lactate release in treated extracts compared to their respective controls. Interestingly, hUCBSC control samples alone showed minimal lactate production ( Figure 5E ). Experiments conducted using hGBM samples showed a relative abundance of lactate compared to the normal brain ( Figure 5F ), indicating that a greater portion of lactate was derived through glycolysis. Taken together, our data show that si-PDK1 not only induced apoptosis, but also reduced EGFR-mediated cell proliferation and lactate production in GBM.
DCA treatment abrogates EGFR phosphorylation and suppresses the tumorigenic ability of GBM cells in vivo.
Reduced levels of EGFR in si-PDK1-or DCA-treated U251 and 5310 cells prompted us to further study the associated mechanism by using an EGFR phosphorylation antibody array. We be targeted to lung cancer patients bearing active FGFR signaling pathways (28) . In view of these findings, we hypothesized that EGFR phosphorylation might interact and activate PDK1 in GBM. Our findings therefore emphasize the importance of studying the mechanisms linking EGFR with other potential targets, eventually translating to novel treatment strategies.
In high necrotic core areas in any given tumor, the amount of oxygen observed is extremely low, thereby accelerating the cells to adapt to hypoxia-mediated by HIF-1 stabilization. Further, HIF-1 is known to transcribe and express several glycolytic genes that critically regulate cell death and apoptosis including PDK1 and EGFR (20, 29, 30) . In this study, we confirmed that both PDK1 and EGFR expression were significantly correlated with HIF-1Į expression in both in vitro and in vivo experiments. Since PDK1 and EGFR reside in different subcellular compartments, we questioned their location of intracellular interaction. PDK1 is known to function in the mitochondria and a few studies have already confirmed that EGFR translocates to the mitochondria (24, 31) . To begin addressing this question, we conducted immunofluorescence studies and found that PDK1 co-localizes with EGFR in the mitochondrial matrix.
Our question whether hypoxia meditated by HIF-1Į activation affects EGFR-PDK1 localization was addressed by observing increased EGFR-PDK1-COX2 interaction in hypoxic conditions, when compared to decreased or minimal interaction in normoxic conditions, suggesting that hypoxia meditated by HIF-1Į stabilization may be required for PDK1 and EGFR interaction ( Figure 5G ). Although this mechanism appears speculative, PDK1-EGFR interaction might provide starting points in targeting glioma cell metabolism. 
umbilical cord blood can be effectively used as an alternative therapy in targeting GBM (14) .
Here, immunohistochemical analysis revealed that hUCBSC treatment reduced EGFR-PDK1 interaction and subcellular fraction experiments and further showed that hUCBSC effectively reduced EGFR and PDK1 expression, both at the mitochondrial and the cytoplasmic levels.
Further studies are warranted to determine how hUCBSC functionally regulates cancer cell metabolism. We also were able to demonstrate that silencing of PDK1 exhibited apoptotic and anti-proliferative effects on U251 and 5310 cells. Our results presented in this study correlated with previous reports regarding the effect of DCA (32). Additionally, both si-PDK1 and DCA treatments suppressed lactate production in U251 and 5310 cell lines, and sh-EGFR treatment also demonstrated similar results. Conversely, hGBM tissues demonstrated a great fold of lactate production confirming the occurrence of typical metabolic remodeling reflective of the Warburg effect. Collectively, the effect of siPDK1, DCA and sh-EGFR treatment shifted U251 and 5310 glioma cell metabolism towards oxidative phosphorylation. Preliminary data supporting the use of DCA in GBM begs further analysis, particularly with regard to ubiquitous EGFR-mediated growth mechanisms. Here, we sought to verify if DCA treatment reduces EGFR-PDK1 interaction, although previous reports substantiate its activity against PDKII in GBM (18).
Our observations with DCA suggested that inhibition of either PDK1 or EGFR or both may affect cancer cell metabolism in vitro. These findings compelled us to explore the existence of an uncovered mechanism by which PDK1 regulates EGFR and its activity. In order to explain this, we used an EGFR phosphorylation antibody array. It was interesting to find that DCA- All experiments were performed in triplicate (n=3). Results from three independent experiments are shown as mean ± SE (*p<0.05; **p<0.01). 
